Thus, anti-CTLA-4 and anti-PD-1 mAbs restore anti-tumor activity by facilitating the differentiation or the reactivation of tumor-reactive cytotoxic CD8+ T cells and of helper CD4+ T cells. Here, CD8A is linked to neoplasm.